

# John Neil Primrose

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/3386668/john-neil-primrose-publications-by-year.pdf>

**Version:** 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

59  
papers

5,639  
citations

27  
h-index

65  
g-index

65  
ext. papers

6,924  
ext. citations

7.8  
avg, IF

4.96  
L-index

#	Paper	IF	Citations
59	Laparoscopic versus open resections in the posterosuperior liver segments within an enhanced recovery programme (ORANGE Segments): study protocol for a multicentre randomised controlled trial.. <i>Trials</i> , <b>2022</b> , 23, 206	2.8	0
58	Long-Term Outcomes and Exploratory Analyses of the Randomized Phase III BILCAP Study.. <i>Journal of Clinical Oncology</i> , <b>2022</b> , JCO2102568	2.2	4
57	Intrahepatic cholangiocarcinoma as the new field of implementation of laparoscopic liver resection programs. A comparative propensity score-based analysis of open and laparoscopic liver resections. <i>Surgical Endoscopy and Other Interventional Techniques</i> , <b>2021</b> , 35, 1851-1862	5.2	15
56	Comment on "Considerations for the treatment of pancreatic cancer during the COVID-19 pandemic: the UK consensus position". <i>British Journal of Cancer</i> , <b>2021</b> , 124, 678	8.7	1
55	Circulating tumour DNA as a biomarker in resectable and irresectable stage IV colorectal cancer; a systematic review and meta-analysis. <i>European Journal of Cancer</i> , <b>2021</b> , 144, 368-381	7.5	11
54	Intratumoural immune signature to identify patients with primary colorectal cancer who do not require follow-up after resection: an observational study. <i>Health Technology Assessment</i> , <b>2021</b> , 25, 1-32	4.4	
53	Comprehensive Imaging Characterization of Colorectal Liver Metastases.. <i>Frontiers in Oncology</i> , <b>2021</b> , 11, 730854	5.3	1
52	The impact of enhanced recovery on open and laparoscopic liver resections. <i>Updates in Surgery</i> , <b>2020</b> , 72, 649-657	2.9	1
51	Hepatic metastases resection after cetuximab: are we missing something? - AuthorsReply. <i>Lancet Oncology, The</i> , <b>2020</b> , 21, e229	21.7	1
50	Systemic chemotherapy with or without cetuximab in patients with resectable colorectal liver metastasis (New EPOC): long-term results of a multicentre, randomised, controlled, phase 3 trial. <i>Lancet Oncology, The</i> , <b>2020</b> , 21, 398-411	21.7	85
49	The Miami International Evidence-based Guidelines on Minimally Invasive Pancreas Resection. <i>Annals of Surgery</i> , <b>2020</b> , 271, 1-14	7.8	136
48	Current standards and future perspectives in adjuvant treatment for biliary tract cancers. <i>Cancer Treatment Reviews</i> , <b>2020</b> , 84, 101936	14.4	34
47	Development and validation of a model to predict outcomes of colon cancer surveillance. <i>Cancer Causes and Control</i> , <b>2019</b> , 30, 767-778	2.8	2
46	Myosteatosis is associated with poor physical fitness in patients undergoing hepatopancreatobiliary surgery. <i>Journal of Cachexia, Sarcopenia and Muscle</i> , <b>2019</b> , 10, 860-871	10.3	21
45	Capecitabine compared with observation in resected biliary tract cancer (BILCAP): a randomised, controlled, multicentre, phase 3 study. <i>Lancet Oncology, The</i> , <b>2019</b> , 20, 663-673	21.7	392
44	Adjuvant Therapy for Resected Biliary Tract Cancer: ASCO Clinical Practice Guideline. <i>Journal of Clinical Oncology</i> , <b>2019</b> , 37, 1015-1027	2.2	157
43	Hepatic Resection Following Selective Internal Radiation Therapy for Colorectal Cancer Metastases in the FOXFIRE Clinical Trial: Clinical Outcomes and Distribution of Microspheres. <i>Cancers</i> , <b>2019</b> , 11,	6.6	5

42	Evaluation and management of incidental gallbladder cancer. <i>Chinese Clinical Oncology</i> , <b>2019</b> , 8, 37	2.3	6
41	Surgical leadership: the British concept. <i>Innovative Surgical Sciences</i> , <b>2019</b> , 4, 65-67	0.8	
40	Minimally Invasive versus Open Distal Pancreatectomy for Ductal Adenocarcinoma (DIPLOMA): A Pan-European Propensity Score Matched Study. <i>Annals of Surgery</i> , <b>2019</b> , 269, 10-17	7.8	132
39	Laparoscopic versus open major hepatectomy: a systematic review and meta-analysis of individual patient data. <i>Surgery</i> , <b>2018</b> , 163, 985-995	3.6	100
38	Association between density of tumor infiltrating lymphocytes and disease-free survival (DFS) in patients with resected stage I-III colorectal cancer in the FACS randomized trial.. <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, 3573-3573	2.2	1
37	Assessment of Nuclear ZEB2 as a Biomarker for Colorectal Cancer Outcome and TNM Risk Stratification. <i>JAMA Network Open</i> , <b>2018</b> , 1, e183115	10.4	17
36	Diagnosis and management of pancreatic cancer in adults: A summary of guidelines from the UK National Institute for Health and Care Excellence. <i>Pancreatology</i> , <b>2018</b> , 18, 962-970	3.8	41
35	The value of tumour debulking for patients with extensive multi-organ metastatic colorectal cancer. <i>European Journal of Cancer</i> , <b>2018</b> , 103, 160-164	7.5	5
34	Exosomal microRNAs derived from colorectal cancer-associated fibroblasts: role in driving cancer progression. <i>Aging</i> , <b>2017</b> , 9, 2666-2694	5.6	84
33	Association between miR-31-3p expression and cetuximab efficacy in patients with KRAS wild-type metastatic colorectal cancer: a post-hoc analysis of the New EPOC trial. <i>Oncotarget</i> , <b>2017</b> , 8, 93856-93866	3.3	31
32	What carcinoembryonic antigen level should trigger further investigation during colorectal cancer follow-up? A systematic review and secondary analysis of a randomised controlled trial. <i>Health Technology Assessment</i> , <b>2017</b> , 21, 1-60	4.4	14
31	A randomised controlled trial to assess the cost-effectiveness of intensive versus no scheduled follow-up in patients who have undergone resection for colorectal cancer with curative intent. <i>Health Technology Assessment</i> , <b>2017</b> , 21, 1-86	4.4	31
30	The clinical and biological significance of MIR-224 expression in colorectal cancer metastasis. <i>Gut</i> , <b>2016</b> , 65, 977-989	19.2	99
29	Outcome and Learning Curve in 159 Consecutive Patients Undergoing Total Laparoscopic Hemihepatectomy. <i>JAMA Surgery</i> , <b>2016</b> , 151, 923-928	5.4	63
28	Patterns of progression, treatment of progressive disease and post-progression survival in the New EPOC study. <i>British Journal of Cancer</i> , <b>2016</b> , 115, 420-4	8.7	7
27	Authentication and characterisation of a new oesophageal adenocarcinoma cell line: MFD-1. <i>Scientific Reports</i> , <b>2016</b> , 6, 32417	4.9	15
26	Site and Stage of Colorectal Cancer Influence the Likelihood and Distribution of Disease Recurrence and Postrecurrence Survival: Data From the FACS Randomized Controlled Trial. <i>Annals of Surgery</i> , <b>2016</b> , 263, 1143-7	7.8	37
25	Tumour infiltrating lymphocytes correlate with improved survival in patients with oesophageal adenocarcinoma. <i>Cancer Immunology, Immunotherapy</i> , <b>2016</b> , 65, 651-62	7.4	67

24	Cetuximab Is Contraindicated in the Perioperative Treatment of Colorectal Liver Metastases. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, 2405-6	2.2	7
23	Natural killer cell maturation markers in the human liver and expansion of an NKG2C+KIR+ population. <i>Lancet, The</i> , <b>2015</b> , 385 Suppl 1, S45	4.0	16
22	Adjuvant chemotherapy with gemcitabine and cisplatin compared to observation after curative intent resection of cholangiocarcinoma and muscle invasive gallbladder carcinoma (ACTICCA-1 trial) - a randomized, multidisciplinary, multinational phase III trial. <i>BMC Cancer</i> , <b>2015</b> , 15, 564	4.8	125
21	A top-down view of the tumor microenvironment: structure, cells and signaling. <i>Frontiers in Cell and Developmental Biology</i> , <b>2015</b> , 3, 33	5.7	52
20	Adjuvant chemotherapy with gemcitabine and cisplatin compared to observation after curative intent resection of cholangiocarcinoma and muscle invasive gallbladder carcinoma (ACTICCA-1): A randomized, multidisciplinary, multinational phase III trial.. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, TPS4140-TPS4140	2.2	1
19	Stratifying risk of recurrence in stage II colorectal cancer using deregulated stromal and epithelial microRNAs. <i>Oncotarget</i> , <b>2015</b> , 6, 7262-79	3.3	33
18	Use of FLIM histology-based HER2-HER3 heterodimer quantification and a Bayesian latent class proportional hazards model to predict cetuximab response in the COIN and new EPOC trials.. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, e14535-e14535	2.2	
17	Association between c-Met expression, miR-31-3p expression and progression free survival in the New EPOC study.. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, 3545-3545	2.2	
16	Cetuximab for resectable colorectal liver metastasis: new EPOC trial--author's reply. <i>Lancet Oncology, The</i> , <b>2014</b> , 15, e306	21.7	3
15	Systemic chemotherapy with or without cetuximab in patients with resectable colorectal liver metastasis: the New EPOC randomised controlled trial. <i>Lancet Oncology, The</i> , <b>2014</b> , 15, 601-11	21.7	298
14	Effect of 3 to 5 years of scheduled CEA and CT follow-up to detect recurrence of colorectal cancer: the FACS randomized clinical trial. <i>JAMA - Journal of the American Medical Association</i> , <b>2014</b> , 311, 263-70	27.4	278
13	Mir-31-3p as a predictive biomarker of cetuximab effects in a post hoc analysis of new EPOC phase III trial.. <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, 3523-3523	2.2	2
12	Patterns of progression, treatment of progressive disease, and postprogression survival in the new EPOC study.. <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, 3556-3556	2.2	3
11	Assessment of the financial implications for laparoscopic liver surgery: a single-centre UK cost analysis for minor and major hepatectomy. <i>Surgical Endoscopy and Other Interventional Techniques</i> , <b>2013</b> , 27, 2542-50	5.2	52
10	Perioperative FOLFOX4 chemotherapy and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC 40983): long-term results of a randomised, controlled, phase 3 trial. <i>Lancet Oncology, The</i> , <b>2013</b> , 14, 1208-15	21.7	733
9	A randomized clinical trial of chemotherapy compared to chemotherapy in combination with cetuximab in k-RAS wild-type patients with operable metastases from colorectal cancer: The new EPOC study.. <i>Journal of Clinical Oncology</i> , <b>2013</b> , 31, 3504-3504	2.2	26
8	Survival after liver resection in metastatic colorectal cancer: review and meta-analysis of prognostic factors. <i>Clinical Epidemiology</i> , <b>2012</b> , 4, 283-301	5.9	371
7	Predictive factors for the benefit of perioperative FOLFOX for resectable liver metastasis in colorectal cancer patients (EORTC Intergroup Trial 40983). <i>Annals of Surgery</i> , <b>2012</b> , 255, 534-9	7.8	76

6	EORTC liver metastases intergroup randomized phase III study 40983: Long-term survival results.. <i>Journal of Clinical Oncology</i> , <b>2012</b> , 30, 3508-3508	2.2	20
5	Short- and long-term outcomes after laparoscopic and open hepatic resection: systematic review and meta-analysis. <i>Hpb</i> , <b>2011</b> , 13, 295-308	3.8	147
4	Single-centre comparative study of laparoscopic versus open right hepatectomy. <i>Journal of Gastrointestinal Surgery</i> , <b>2011</b> , 15, 818-23	3.3	284
3	Lung metastasectomy in colorectal cancer: is this surgery effective in prolonging life?. <i>Respirology</i> , <b>2010</b> , 15, 742-6	3.6	25
2	Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial. <i>Lancet, The</i> , <b>2008</b> , 371, 1007-16	4.0	1468
1	Hdm2 Recruits the Hypoxia Sensitive Transcriptional Co-Repressor CtBP2 to Negatively Regulate p53-Dependant Transcription. <i>Clinical Science</i> , <b>2003</b> , 104, 29P-29P		